Peptide News Digest

#Bria-Imt

2 stories

Clinical Trials · View digest

BriaCell Announces Six Bria-IMT Peptide Immunotherapy Presentations at ASCO 2026 Including 12- and 24-Month Survival Update

BriaCell announced April 27 that its Bria-IMT cell-based peptide immunotherapy will be featured in three poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). Highlights include 12- and 24-month overall survival data with Bria-IMT plus checkpoint inhibition in advanced metastatic breast cancer, an updated quality-of-life and tolerability analysis, and a randomized Bria-ABC Phase 3 blood-biomarker progression-free survival readout. Three publication-only abstracts cover the second-generation BC1 platform, multi-analyte liquid biopsy stratification, and PD-L1 monitoring in circulating cancer-associated cells.

Clinical Trials · View digest

BriaCell Bria-IMT Phase 3 Peptide Vaccine Preserves Quality of Life in Heavily Pretreated Breast Cancer

BriaCell's Bria-IMT + checkpoint inhibitor combination preserved overall health status and key functional quality-of-life measures in its pivotal Phase 3 study in heavily pretreated metastatic breast cancer patients who had failed ADC, CPI, and CDK4/6 inhibitor therapy. Phase 2 biomarker analyses identified mitotic circulating tumor cells as prognostic and PD-L1 in tumor-macrophage fusion cells as predictive of checkpoint benefit. Presented at AACR April 20.